AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
October 03 2008 - 9:30AM
PR Newswire (US)
TUSTIN, Calif., Oct. 3 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL, Inc. (AMEX:ADL), a leading vertically
integrated bio-pharmaceutical company with major operations in
China and the US, today announced that the Company will present at
the Maxim Group Growth Investor Conference in New York City on
Tuesday, October 7, 2008 at 10:30 a.m. ET. AMDL's presentation will
be held at the Grand Hyatt New York Hotel in the Morosco Room. The
Maxim Group Growth Conference features interactive presentations
and one-on-one meetings with executives from over 80 emerging
growth companies within various sectors including healthcare and
pharmaceuticals. Attendees include securities analysts, fund
managers and institutional investors. AMDL, Inc. is a specialty
pharmaceutical Company devoted to the research, development,
manufacturing, and marketing of over 180 diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products in
China and outlying markets. This year alone, the Company has
secured over $25 million in sales contracts for its best-selling
Goodnak(R) anti-aging product; expanded the Goodnak(R) revenue
opportunity with the launch of two additional product formulations
that include Goodnak(R) capsules and Goodnak(R) lotions; and
secured US FDA clearance on July 3, 2008 for its ELISA DR-70(R) FDP
cancer diagnostic test - the first test to be cleared by the US FDA
in over 25 years for the monitoring of colorectal cancer. These are
a few milestones AMDL's Board Chairman and Audit Committee Chair
Mr. Douglas MacLellan will highlight in a presentation which will
also cover AMDL's market opportunity as an aggressively growing
micro-cap investment opportunity in the China specialty
pharmaceuticals sector. He will also provide insight on AMDL's
growth strategy, product portfolio and 2008 financial projections.
The presentation will be live-broadcast over the Internet and
archived for 90 days. Interested parties may listen to the
presentation by visiting the Investor Information section of the
Company's website at: http://www.amdl.com/ . About AMDL:
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi,
and Jilin, China, AMDL, Inc., along with its subsidiary Jade
Pharmaceutical Inc. (JPI), is a vertically integrated
bio-pharmaceutical company devoted to the research, development,
manufacturing, and marketing of diagnostic, pharmaceutical,
nutritional supplement, and cosmetic products. The Company employs
approximately 320 people in the U.S. and China. The Company has an
additional 4 pharmaceutical and diagnostic products under review by
various regulatory authorities. Forward Looking Statements: Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: The statements contained in this document include certain
predictions and projections that may be considered forward-looking
statements under securities law. These statements involve a number
of important risks and uncertainties that could cause actual
results to differ materially including, but not limited to, the
performance of joint venture partners, as well as other economic,
competitive and technological factors involving the Company's
operations, markets, services, products, and prices. With respect
to AMDL, Inc., except for the historical information contained
herein, the matters discussed in this document are forward-looking
statements involving risks and uncertainties that could cause
actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
related to the Company's access to additional capital, competition
and dependence on key management. AMDL Contact: Kristine Szarkowitz
Director-Investor Relations (M) (206) 310-5323 DATASOURCE: AMDL,
Inc. CONTACT: Kristine Szarkowitz, Director-Investor Relations of
AMDL, +1-206-310-5323, Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024